Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Genzyme, Alnylam Announce MAA Submission | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Sanofi Genzyme, Alnylam Announce MAA Submission

For patisiran, an investigational drug for the treatment of adults with amyloidosis

By: Betsy Louda

, Contract Pharma

Sanofi Genzyme and Alnylam Pharmaceuticals announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). Patisiran was previously granted accelerated assessment by the EMA, potentially reducing the EMA’s evaluation time from 210 to 150 days.

 

“People with hATTR amyloidosis have limited treatment options,” said Rand Sutherland, M.D., therapeutic area head of Rare Diseases Development at Sanofi. “With this MAA submission, we are one step closer to making patisiran available in Europe and executing on our shared vision to bring this RNAi treatment to patients globally.”

 

Patisiran has not been approved by the FDA, EMA, or any other regulatory authority and no conclusions can or should be drawn regarding the safety or effectiveness of this investigational therapeutic.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics